Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Guesses on the next big news release?

<< Previous

Bullboard Posts

Next >>

Comment by Nick80on Mar 29, 2021 2:19pm

128 Views

Post# 32899504

RE:RE:Guesses on the next big news release?

*If they can quickly come up with a potential Alzheimer's candidate than we likely have one for Parkinson's and other brain related indications (like Central Sleep Apnea and a general anti-aging drug for brain cells) as well. This could become a once-a-day along with Aspirin for everyone over 50. See how we get into the wellness market? Skru the vitamin market - we've got our own daily !!!!*

What makes you say that they have a new drug like that? Did I miss a release them stating they or their platform would targeting Alzheimers, etc..?

<< Previous

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment